Rapport Therapeutics reported that RAP-219 achieved statistically significant primary and secondary endpoints in a Phase 2 ...
Rapport Therapeutics has seen a sharp pullback recently, and that slump puts fresh focus on whether the current share price ...
Positive trial data for Rapport’s lead pipeline candidate, RAP-219, a treatment for bipolar mania, points to a potential $1 ...
Rapport Therapeutics clocked its second Phase 2 win in 14 months for RAP-219—which the company is positioning as a potential ...
Investor's Business Daily on MSN
Can this small biotech enter a $4.3 billion AbbVie market? Rapport rises
Rapport Therapeutics stock jumped Tuesday on promising, but mixed, test results for its bipolar treatment.
Rapport Therapeutics, Inc.'s RAP-219 delivered impressive Phase 2a results in drug-resistant focal onset seizures, driving Rapport Therapeutics' stock up over 135% and boosting investor optimism. The ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results